Zobrazeno 1 - 10
of 3 270
pro vyhledávání: '"K. Brun"'
Autor:
I. Sapozhnikov, M. Kashuba
Publikováno v:
Archaeological News. 32:452-461
This paper is devoted to the brief but successful collaboration in the 1860s between the Imperial Archaeo- logical Commission (IAC) and the Odessa scholar of German origin F. K. Brun (Philipp Jakob Bruun) (1804–1880). This episode is recorded in a
Publikováno v:
American Journal of Medical Genetics. Part A; January 2007, Vol. 143 Issue: 2 p142-148, 7p
Publikováno v:
SIAM Journal on Applied Mathematics
This paper concerns the modeling and numerical simulation of the process of speciation. In particular, given conditions for which one or more speciation events within an ecosystem occur, our aim is to develop the necessary modeling and simulation too
Autor:
K Bjørlykke, M K Brun, M K Viken, G E Stenvik, R A Klaasen, J E Gehin, D J Warren, J Sexton, E A Haavardsholm, J Jahnsen, B A Lie, G L Goll, N Bolstad, S W Syversen, K K Jørgensen
Publikováno v:
Journal of Crohn's and Colitis. 16:i594-i595
Background Immunogenicity is a leading cause of treatment failure to TNF inhibitors. Genetic variations in HLA class II genes have been suggested to predispose to anti-drug antibody formation, but studies using high-resolution HLA typing as well as c
Autor:
M. K. Brun, K. H. Bjørlykke, M. K. Viken, B. Stenvik, R. A. Klaasen, J. Gehin, D. J. Warren, J. Sexton, Ø. Sandanger, C. Mørk, T. K. Kvien, E. A. Haavardsholm, J. Jahnsen, G. L. Goll, B. A. Lie, K. K. Jørgensen, N. Bolstad, S. W. Syversen
Publikováno v:
Annals of the Rheumatic Diseases. 81:216.2-217
BackgroundImmunogenicity is a leading cause of treatment failure to TNF inhibitors, and also affects drug safety. Variations in HLA class II genes have been suggested to predispose to anti-drug antibody formation (ADA), but characterisation of biolog
Autor:
Kristin K. Joergensen, Silje W Syversen, Guro L. Goll, Kristin H. Bj⊘rlykke, Øystein Sandanger, Joe Sexton, Marthe K. Brun, Cato M⊘rk, Tore K. Kvien, Johanna E. Gehin, Inge C Olsen, Nils Bolstad, Espen A. Haavardsholm, Jorgen Jahnsen
Publikováno v:
Gastroenterology. 162:S-44
Autor:
Kristin H. Bj⊘rlykke, Marthe K. Brun, Marte K. Viken, Grethe-Elisabeth Stenvik, Rolf A. Klaasen, Johanna E. Gehin, David J. Warren, Joe Sexton, Espen A. Haavardsholm, Jorgen Jahnsen, Benedicte A. Lie, Guro L. Goll, Nils Bolstad, Silje W Syversen, Kristin K. J⊘rgensen
Publikováno v:
Gastroenterology. 162:S-17
Autor:
K K Jørgensen, S W Syversen, G L Goll, K H Bjørlykke, Ø Sandanger, J Sexton, M K Brun, G Noraberg, C M Ystrøm, K A Seeberg, I M Blomgren, R Torp, C Mørk, T K Kvien, N Bolstad, E A Haavardsholm, J Jahnsen
Publikováno v:
Journal of Crohn's and Colitis. 16:i010-i010
Background Proactive therapeutic drug monitoring (TDM), individualized treatment based on scheduled assessments of serum drug levels, has been proposed to optimize efficacy and safety of infliximab and other biologic drugs. However, it is unclear whe
Autor:
David J. Warren, Silje W Syversen, K. K. Jørgensen, Nils Bolstad, C. Mørk, Joseph O. Sexton, Rolf Anton Klaasen, T.K. Kvien, M. K. Brun, Øystein Sandanger, Inge C. Olsen, G. L. Goll, Jørgen Jahnsen, J. E. Gehin, Espen A Haavardsholm
Publikováno v:
Annals of the Rheumatic Diseases. 80:185.2-185
Background:Immunogenicity is related to loss of efficacy and safety to TNFα inhibitors and is frequently observed early in the treatment course. The highest rate of anti-drug antibody (ADAb) formation has been reported for infliximab (IFX). 1 Knowle
Autor:
Silje W Syversen, G. L. Goll, Espen A Haavardsholm, K. K. Jørgensen, Inge C. Olsen, Joseph O. Sexton, T.K. Kvien, Jørgen Jahnsen, Nils Bolstad, C. Mørk, David J. Warren, M. K. Brun, J. E. Gehin, Øystein Sandanger
Publikováno v:
Annals of the Rheumatic Diseases. 79:12-12
Background:A lack or loss of response to TNFα inhibitors (TNFi) has been associated with low serum drug levels and formation of anti-drug antibodies (ADAb). Therapeutic drug monitoring (TDM), an individualised treatment strategy based on regular ass